---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-24-000058"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:27:19.025913+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions to cut ~300 jobs, close two facilities, targeting $80M annual savings

## Summary
- Reduces workforce by ~300 employees and eliminates ~85 vacant positions across all areas.
- Closes Baltimore-Bayview Drug Substance and Rockville Drug Product manufacturing facilities.
- Estimated charges of $18-21M primarily in H2 2024; expects annualized savings of ~$80M.
- Operations concentrated at Winnipeg and Lansing; new Chief Science Officer role created.
- Q1 2024 earnings to be reported May 1; also filed amendment to credit facility.

## SEC filing metadata
- accession: 0001367644-24-000058
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000058/0001367644-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764424000058/ebs-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-24-000058
- JSON: https://secwatch.observer/filing/0001367644-24-000058.json
- Plain text: https://secwatch.observer/filing/0001367644-24-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.